Aarti Drugs Ltd

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.12%, the pharmaceutical company’s technical landscape remains complex, with mixed signals across weekly and monthly charts suggesting cautious investor sentiment amid broader market challenges.

Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player.

The Sensex declined by 2.15% on 1 Apr 2026, yet Aarti Drugs Ltd surged 7.65%, marking a 6.28 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine recovery or a technical bounce within a broader downtrend.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening 6.63% lower at Rs 342.65, reflecting heightened market apprehensions following recent developments. The stock’s weak start underscores ongoing pressures within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and the broader market indices.

Aarti Drugs Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating technical indicators and disappointing financial performance. The company’s Mojo Score has slipped to 28.0, signalling heightened caution for investors amid a bearish technical outlook, weakening profitability, and subdued valuation metrics despite some operational strengths.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a more pronounced bearish trend. Despite a marginal day decline of 0.23%, the stock’s technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, signal increasing downside pressure. This comprehensive analysis explores the evolving technical landscape of Aarti Drugs Ltd, contextualising its performance against broader market benchmarks and sector dynamics.

Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 February 2026, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s Mojo Score has improved to 34.0, signalling a cautious but more optimistic stance amid mixed performance across quality, valuation, financial trends, and technical indicators.

Aarti Drugs Ltd has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.22%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid ongoing sector challenges.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into the company’s performance and outlook.